Navigation Links
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
Date:12/10/2007

0,000-30,000 new cases of MDS are diagnosed each year in the United States, although it is difficult to accurately determine the incidence because MDS is not a disease for which the Centers for Disease Control and Prevention (CDC) mandates reporting of cases.

Important Vidaza Safety Information

Vidaza is contraindicated in patients with a known hypersensitivity to Vidaza or mannitol and in patients with advanced malignant hepatic tumors.

In clinical studies, the most commonly occurring adverse reactions by SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse reactions by IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%) and hypokalemia (31.3%).

Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle.

Because Vidaza is potentially hepatotoxic in patients with severe pre- existing hepatic impairment, caution is needed in patients with liver disease. In addition, Vidaza and its metabolites are substantially excreted by the kidneys and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Vidaza may cause fetal harm. While receiving treatment with Vidaza, women of childbearing potential should avoid becoming pregnant, and men should avoid fathering a child. In additi
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... TX (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle ... guide that teaches people how to cure their nasal ... to readers the horrible truth about conventional treatments for nasal ... this book, people will learn how to prevent symptoms ... nasal infections. , Nasal Polyps Treatment Miracle, as it is ...
(Date:7/30/2014)... Francisco, CA (PRWEB) July 30, 2014 ... capture and physician communication, launched an Observation Result ... in the hospital. pMD’s cardiology customers are using ... optimize revenue for their test interpretations for electrocardiograms, ... interprets tests in the hospital, the cardiology system ...
(Date:7/29/2014)... Rancho Cucamonga, CA (PRWEB) July 29, 2014 ... “Realistic Ways to Make More Money in 30 Days” E-book. ... that anyone can use to make extra cash. Examples include ... and utilizing unique free websites that help people monetize the ... bedroom, and even unused items they can find in their ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced ... on Monday, March 9, 2009, at 4:30 p.m. EDT to ... results, and provide an update on recent corporate developments. To ... The live Webcast and replay access of the teleconference will ...
... Inc. (NYSE: CRE ), today announced that it will release ... market opens on Monday, March 16, 2009.The Company will host ... a.m. Eastern Time to discuss fourth quarter and year end ... dialing 800-240-2430 or by visiting the Company,s website at ...
... ... physicians and specialists , Kuala ... Asia the release of Centricity PACS Web Diagnostic (WebDX),a new Web-based ... RIS/ PACS, which bring comprehensive detailed patient,history to a single patient ...
... OF PRUSSIA, Pa., Feb. 27 Fourth quarter of ... Realty Income Trust (NYSE: UHT ) announced today ... net loss was $870,000, or $.07 per diluted share, as ... per diluted share, during the comparable quarter in the prior ...
... University of Pittsburgh Medical Center (UPMC) and Paphos Plantations Ltd. (PPL) - ... collaborating to develop a world-class health care center in Paphos, Cyprus, designed ... and foreign visitors to this Mediterranean island. , ... Pittsburgh, PA and ...
... to the media regarding the PLoS Medicine article published online ... patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated ... 2001. , ... San Diego, California ...
Cached Medicine News:Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 2Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 11Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 12Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 2Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 3Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 2Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 5
(Date:7/29/2014)... -- Covance Inc. (NYSE: CVD ) today reported ... Net revenue was $639 million, representing 8.0% growth from ... the company reported earnings of $0.29 per diluted share ... earnings per diluted share of $0.95, up 21.5% over ... asset impairment charges totaling $52.6 million, or $0.61 per ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... SPRINGS, Colo. , July 29, 2014 ... catheter (MARC) which could allow physicians to see and ... may hold promise, according to study authors who released ... (SNIS) 11 th Annual Meeting in ... stand to advance the field of neurointervention, a specialty ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
Khosla Precision and Quality in Medical and Surgical Products....
...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Medicine Products: